Background and aims: The presented work is based on the results of our published work, in which we focused on the VNS efficacy prediction in patients with drug-resistant epilepsy. We found that there are differences in power spectra between VNS responders and non-responders. We asked two more questions. Are there differences between the epileptic patients with VNS and healthy controls? Do the EEG power spectra in healthy controls resemble more responders or non-responders to VNS therapy? Methods: We identified retrospectively EEG recording in epileptic patients with VNS and in healthy controls. The epileptic patients were classified based on the VNS efficacy as responder and non-responders EEG was segmented into several time-intervals (resting-state, eyes-opening 1, resting state, photic stimulation, hyperventilation, eyes opening 2, resting state 3 and resting state) and frequency bands. Subsequently, we established relative EEG power spectra in pre-defined frequency bands and time-intervals. Results: We identified EEG in 56 healthy controls and in 60 epileptic patients with VNS (35 responders, 25 non-responders). When compared healthy controls and epileptic patients, we identified EEG power spectra differences in theta (eyes-opening 1, 2), alpha (eyes-opening 1,2) and beta frequency range (eyes-opening 1). When compared responders to VNS therapy and healthy controls, we found more significant differences than in non-responders.